What this study is
The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prespecified cancers of interest. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.
What's being tested
- Bio-specimen Collection
Intervention · OTHER
Tissue samples will be taken from existing archived collections and sent for further analysis.
- Blood Draw
Intervention · OTHER
Blood samples will be collected within the first year of enrollment.
Study details
- Sponsor
- University of Oklahoma
- Conditions
- Prostate Cancer · Renal Cell Carcinoma (RCC)
- Enrolling
- 300 people
- Starts
- 2026-11-02
- Est. completion
- 2029-10-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 100 YearsSex MALEHealthy volunteers Not acceptedYou may qualify if
- Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
- At least 18 years-of-age at the time of signature of the informed consent form (ICF).
- Patients who self-identify as Native American.
- Patients with a pathologically proven diagnosis of PC and RCC (any stage).
- Availability of most recent archived tumor samples.
You can't join if
- Patients not of Native American descent or identity.
- Patient does not have archival tissue available.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openOU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Adanma Ayanambakkam, MD · Contact405-271-4022Adanma-Ayanambakkam@ou.edu
Recruiting
Study team
Sponsor
University of Oklahoma
Study ID OU-SCC-NAT-Geno
Principal investigator
Adanma Ayanambakkam, MD, MS
University of Oklahoma
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.